
Towards the Assembly of the Binary *Vinca* Alkaloids: Strategies for the Synthesis of Analogues of the Indole-Indoline Core of (+)- Vinblastine

A thesis submitted for the degree of Doctor of Philosophy
of the Australian National University

by

Michael John Harvey



Research School of Chemistry
Canberra, Australia

June, 2006



Declaration

I declare that the material presented in this thesis represents the result of original work carried out by me during the period 2001-2005 and that it has not been presented for examination for any other degree. Established methodologies have been acknowledged, wherever possible, by citation of the original publications from which they derive. This thesis is less than 100,000 words in length.

Michael John Harvey

June, 2006

“Chemists are a strange class of mortals, impelled by an almost maniacal impulse to seek their pleasures amongst smoke and vapour, soot and flames, poisons and poverty, yet despite these evils I seem to live so sweetly that I would rather die than change places with the King of Persia.”

Johann Joachim Becher in *Physica Subterranea* (1667)

Acknowledgements

To begin with, I would like to thank my supervisor, Professor Martin Banwell, for his contributions towards my thesis. His advice and patience are valued. I also appreciate the opportunity he gave me to conduct my PhD research here in Canberra.

I would also like to thank all the postdoctoral researchers who have been instrumental and influential during my time here at the Research School of Chemistry. In particular I would like to thank Dr Jens Renner for teaching the vagaries of good experimental practice, Dr Steffan Gross for our robust conversations on more theoretical matters and finally, Dr Michael Backes for his pragmatic approach to synthesis when I had a crazy idea to share.

Many research students have come and gone during my stay at the Australian National University and all have helped in some way. I would like to acknowledge the support of Dr David Lupton, who introduced me to the wonderful world of Ullmann and Mr Okanya Kokas who was always willing to listen and discuss ideas of a wide nature.


I would like to thank all the technical staff of the School. I am especially indebted to Tony Herlt (HPLC) and Chris Blake (NMR) for their technical wisdom. I would also like to thank Dr Aaron Oakley for his advice on biomolecular modelling.

To the people that have been closest and most important to me personally during this period in my life – I thank you for your understanding, your support and your unfailing belief in me. Belinda, Kathy and Su Jing, your confidence and encouragement have given me strength.


Finally, my family are the foundation where I came from, and I am grateful for everything that they have done for me so far, and in the future. I am thankful for my mother, father and brother having been encouraging and supportive and, most of all, a comfort, over the telephone during my sojourn in Australia's capital.

Abstract

The clinically important alkaloids (+)-vinblastine (**1**) and (+)-vincristine (**2**) both exhibit extraordinary potency as anti-mitotic agents and act by destabilising polymerised tubulin. While the development of a structure-activity-relationship (SAR) profile around these natural products should allow for the identification of the relevant pharmacophore, this task is especially daunting because of the structural complexity of these compounds. Indeed, most analogues of the *Vinca* alkaloids are obtained through modifications of the natural products rather than being generated *de novo* by “total synthesis”.




In principle, a useful starting point in generating small molecule analogues of the title alkaloids that may well retain useful biological properties would be to prepare a series of compounds mimicking the indole-indoline core of (+)-vinblastine (**1**) and involving a range of different pairings of aryl groups as surrogates for these heterocyclic units. This approach, which would lead to compounds such as **175**, requires establishing methods for the generation and appropriate linking of these units.




The methodology ultimately established for obtaining the abovementioned (+)-vinblastine analogues is detailed in Chapter Two and involved Pinhey-type arylation of α -carbomethoxylated cycloalkenones such as **75** with the relevant plumbated arenes, *e.g.* **99**. The resulting α -arylated cycloalkenone, *e.g.* **106**, was submitted to a Banwell-type indole synthesis involving α' -iodination of such compounds under conditions defined by Johnson and then subjecting the product of this process, *e.g.* **155**, to a


palladium[0]-catalysed Ullmann cross-coupling reaction with *o*-iodonitrobenzene (**137**). The resulting product, *e.g.* **169**, was then subjected to reductive cyclisation using dihydrogen in the presence of palladium on carbon, and so affording the target mimetics, *e.g.* **175**, of the indole-indoline core of alkaloids **1** and **2**



Attempts, as described in Chapter Three, were then made to extend such chemistry to the preparation of the *bis*-indole **44** containing a tetracyclic structure resembling the carbomethoxyvelbamine portion of (+)-vinblastine (**1**).



The following Chapter (Four) details attempts to extend the methodology introduced in Chapter Two to the enantioselective preparation of vinblastine analogues such as **175**. In particular, the carbomethoxy group associated with the α -carbomethoxycycloalkenone precursors, *e.g.* **75**, to such compounds were replaced by carboalkoxy groups incorporating chiral alcohol residues such as menthol, (1-methyl-1-phenylethyl)cyclohexanol, 8- β -naphthylmenthol and [*N*-benzenesulfonyl-*N*-(3,5-diphenyl)-amino]-2-bornanol and then seeking to effect the diastereoselective Pinhey arylation of these compounds. Some diastereoselection was achieved in this regard when the chiral auxiliary **244** was employed.



Publications and Presentations Carried Out During Period of Candidature

Publications:

“An Evaluation of Functional Group Tolerances in the Johnson-type Synthesis of \pm -Haloenones and in their Palladium[0]-Catalysed Ullman Cross-Coupling Reactions with *o*-Halonitrobenzenes: Application to the Synthesis of a Simple Vinblastine Analogue”. Banwell, M. G., Harvey, M. J., Lupton, D. W., manuscript in preparation, to be submitted to *Organic and Biomolecular Chemistry*.

Presentations:

“Towards the Assembly of the Binary Indole-Indoline Alkaloids: A Strategy for the Construction of the C-16' to C-10 Linkage of (+)-Vinblastine”. Poster presentation at the 39th National Organic Chemistry Symposium (NOS), The University of Utah, Salt Lake City, Utah, June 2005.

Glossary

The following abbreviations and symbols have been used throughout this thesis:

AcOH	acetic acid
Ac	acetyl
Ac ₂ O	acetic anhydride
Ar	Aryl
aq.	aqueous
atm.	atmosphere
BINAP	2,2- <i>bis</i> (diphenylphosphino)-1-1' binaphthyl
Bn	benzyl
bipy	2,2'-bipyridyl
Boc	<i>tert</i> -butoxycarbonyl
(Boc) ₂ O	di- <i>tert</i> -butyldicarbonate
b.p.	boiling point (°C)
Bu	butyl
<i>n</i> -BuLi	<i>n</i> -butyllithium
<i>t</i> -Bu	<i>tertiary</i> -butyl
<i>t</i> -BuLi	<i>tertiary</i> -butyllithium
<i>c</i>	concentration (g/100 mL)
<i>ca.</i>	<i>circa</i> (approximately)
conc.	concentrated
COSY	homonuclear (¹ H/ ¹ H) correlation spectroscopy
d	doublet
δ	chemical shift (parts per million)

DCM	dichloromethane
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DEPT	distortionless enhancement of polarisation transfer
DNA	deoxyribonucleic acid
dm	decimetre
DMAP	4-(<i>N,N</i> -dimethylamino)pyridine
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethyl sulfoxide
dppp	1,4- <i>bis</i> (diphenylphosphino)propane
d.r.	diastereomeric ratio
<i>e.g.</i>	<i>exemplia gratia</i>
e.e.	enantiomeric excess
<i>E</i>	<i>entgegen</i> (opposite)
EI	electron impact
ether	diethyl ether
equiv. or eq.	equivalents
ESI	electrospray ionisation
Et	ethyl
Et ₃ N	triethylamine
eV	electron volt
FTIR	fourier transform infrared
g	gram
h	hour(s)
Hg(OTf) ₂	mercuric (II) triflate
HMPA	hexamethylphosphoramide
HRMS	high resolution mass spectrum
Hz	Hertz

Im.	imidazole
IR	infrared
<i>J</i>	coupling constant (Hz)
Jones' reagent	Chromic and sulfuric acid in acetone
<i>t</i> -BuOK	potassium <i>tert</i> -butoxide
KHMDS	potassium hexamethyldisilazide
<i>L</i>	length (dm)
LDA	lithium diisopropylamide
lit.	literature
LiHMDS	lithium hexamethyldisilazide
M	Molar (molL ⁻¹)
m	multiplet
M ⁺	molecular ion
Mander's reagent	methyl cyanofornate
Me	methyl
MeCN	acetonitrile
MeOH	methanol
min.	minute(s)
mg	milligram
mL	millilitre
mm	millimetre
mol	mole
mmol	millimole
m.p.	melting point (°C)
MS	mass spectrum
MsCl	methanesulfonyl chloride

m/z	mass-to-charge ratio
nm	nanometre
NaHMDS	sodium hexamethyldisilazide
NMP	<i>N</i> -methylpyrrolidinone
NMR	nuclear magnetic resonance
NOE	nuclear Overhauser enhancement
<i>t</i> -BuONa	sodium <i>tert</i> -butoxide
Ns	2-nitrobenzenesulfonyl
OMe	methoxy
ν_{\max}	infrared absorption maxima (cm^{-1})
p	pentet
<i>p</i> -BQ	<i>para</i> -benzoquinone
$\text{Pd}(\text{PPh}_3)_4$	tetrakis(triphenylphosphine)palladium[0]
$\text{Pd}_2(\text{dba})_3$	tris(dibenzylideneacetone)dipalladium[0]
Ph	phenyl
Piv	pivaloyl
<i>i</i> -Pr	isopropyl
<i>i</i> -Pr ₂ NH	diisopropylamine
py.	pyridine
q	quartet
<i>R</i>	<i>rectus</i>
RCM	ring closing metathesis
R_f	retardation factor
r.t.	room temperature (assumed to be $\sim 18^\circ\text{C}$)
<i>S</i>	<i>sinister</i>
s	singlet
SAR	structure-activity-relationship

sat.	saturated
sept	septet
sex	sextet
(Bu) ₃ SnSn(Bu) ₃	hexabutyl ditin
(Bu) ₃ SnCl	tri- <i>n</i> -tributylstannyl chloride
t	triplet
TBS	<i>tert</i> -butyldimethylsilyl
TBDMS	<i>tert</i> -butyldimethylsilyl
TIPS	triisopropylsilyl
Tf	trifluoromethanesulfonyl
TfOH	trifluoromethanesulfonic acid
TFA	trifluoroacetyl
(TfO) ₂	trifluoromethanesulfonic anhydride
THF	tetrahydrofuran
TiCl ₃ •THF	titanium trichloride tetrahydrofuran complex
TLC	thin layer chromatography
TMS	trimethylsilyl
TMSCl	trimethylsilyl chloride
UV	ultraviolet
v/v	volume ratio
Z	<i>zusammen</i> (together)
<	less than
>	greater than
°C	degrees Celsius
%	percentage
Δ	heating

Table of Contents

Chapter One: The Biological Activity of (+)-Vinblastine and Motives for the Synthesis of Small Molecule Analogues

1.1 Introduction	1
1.1.1 Tubulin and Microtubules.....	1
Microtubules and Mitosis.....	2
The Vinca Alkaloid Binding Site on Tubulin	4
1.2 (+)-Vinblastine	7
1.3 Studies on the C-16' to C-10 Linkage of (+)-Vinblastine	8
1.3.1 The Hydroxyindole Approach	9
1.3.2 The Chloroindolenine Approach	10
1.3.3 The Biomimetic Approach	12
Total Synthesis of (+)-Vinblastine by Kuehne.....	14
Total Synthesis of (+)-Vinblastine by Fukuyama	16
Total Synthesis of (+)-Vinblastine by Magnus	17
1.4 Towards a Synthesis of "Bridging Region" Analogues of (+)-Vinblastine	20
1.5 Aims of the Research Described in this Thesis.....	21
1.5.1 Preparation of "Bridging Region" Analogues of (+)-Vinblastine	21
1.5.2 Development of Carbomethoxyvelbamine Framework.....	22
1.5.3 Controlling the Stereochemistry of C-16' to C-10 Linkage in the Targetted (+)-Vinblastine Analogues	23
1.6 References	24

Chapter Two: The Synthesis of Analogues of the "Bridging Region" or Indole-Indoline Core of (+)-Vinblastine

2.1 Introduction	27
2.1.1 Overview and Context	27
2.2 α -Arylation of β -Ketoesters	28
2.2.1 Background.....	28
Chelation-controlled Heck Reactions	29

Buchwald/Hartwig Palladium Mediated α -Arylations	29
Direct Asymmetric α -Arylations Using Diaryl Iodonium Salts	31
The Pinhey Reaction	33
Preparation of Cyclic β -Ketoesters	34
Preparation of Arylstannanes	35
Preparation of Aryllead Triacetates.....	39
Arylation of β -Ketoesters.....	40
2.3 Synthesis of “Bridging Region” or Indole-Indoline Analogues of (+)-Vinblastine	45
2.3.1 Background.....	45
Fischer’s Indole Synthesis.....	45
The Bischler-Mohlau Indole Synthesis	46
Soderberg’s Indole Synthesis	46
Indole Annulation in Shibasaki’s Synthesis of (-)-Strychnine.....	47
Banwell’s Synthesis of Indoles.....	47
2.4 Application of the Pd[0]-catalysed Ullmann Cross-Coupling Reaction in Preparing “Bridging Region” Analogues of (+)-Vinblastine.....	49
2.4.1 Examining the Scope of Pd[0]-catalysed Ullmann Cross-Coupling Reaction.....	50
Preparation of α' -Iodinated Cross-Coupling Partners.....	51
Cross-Coupling and Reductive Cyclisation	58
2.5 Summary	65
2.6 References	67

Chapter Three: Approaches to the Synthesis of a (+)-Vinblastine Analogue Incorporating a Carbomethoxyvelbamine Framework

3.1 Introduction	69
3.1.1 Overview and Context	69
3.2 Synthetic Strategy for the Preparation of a (+)-Vinblastine Analogue Incorporating a Carbomethoxyvelbamine Framework.....	70
3.3 Synthesis of the Indole Fragment 189	71
3.3.1 Pd[0]-catalysed Ullmann Cross-Coupling Approach	71
3.3.2 Bischler-Mohlau Approach	73

3.4 Attempted Development of Carbomethoxyvelbamine Framework of (+)-Vinblastine	76
3.4.1 Synthesis of β -Ketoester 190	76
Synthesis of Alkyl Iodide 208	79
Preparation of a New Alkylation Partner	81
3.5 A Revised Synthetic Strategy	84
3.5.1 Synthesis of β -Ketoester 217	85
3.5.2 Pinhey Arylation	87
3.6 Summary	89
3.7 References	90

Chapter Four: The Development of a Chiral Auxiliary-based Diastereoselective Pinhey Arylation of Cyclic β -Ketoesters

4.1 Introduction	92
4.1.1 Overview and Context	92
4.1.2 Background	92
Diastereoselective Pinhey α -Arylations	93
4.2 The Use of Chiral Auxiliaries to Develop a Diastereoselective Pinhey Arylation of Cyclic β -Ketoesters	95
4.2.1 Preparation of Chiral Alcohols	96
4.2.2 Preparation of Chiral Chloroformates	98
4.2.3 Preparation of Chiral Cyanoformates	101
4.2.4 Preparation of Chiral β -Ketoesters	104
4.2.5 Diastereoselective Pinhey α -Arylations	105
Effect of Coordinating Base	109
4.3 Summary	111
4.4 Conclusions	111
4.5 References	112

Chapter Five: Experimental Procedures Associated with Work Described in Chapters Two to Four

5.1 General Procedures	114
5.2 Experimental Procedures Associated with Work Described in Chapter Two.....	116
5.2.1 Synthesis of Arylstannanes 92 - 95	117
5.2.2 General Procedure for Synthesis of Aryllead Triacetates 97 - 99	125
5.2.3 General Procedure for Synthesis of Cyclic α -Arylated β -Ketoesters 76, 101 - 110	127
5.2.4 General Procedure for Synthesis of Cyclic α -Arylated Trimethyl Silyl Enol Ethers 143 - 145	134
5.2.5 General Procedure for Synthesis of Cyclic α -Arylated Enones 146 - 148 ...	136
5.2.6 General Procedure for Synthesis of α' -Iodinated Cyclic Enones 138, 149 - 159	138
5.2.7 General Procedure for Pd[0]-catalysed Ullmann Cross-Coupling.....	146
5.2.8 General Procedure for Reductive Cyclisation of (<i>o</i> -Nitrophenyl)cycloalkenone 139, 160 - 163, 166 - 170 and 178 - 181	155
5.2.9 Titanium Trichloride-mediated Reductive Cyclisation	164
5.3 Experimental Procedures Associated with Work Described in Chapter Three...	165
5.3.1 Synthesis of 3-Bromo-6,7,8,9-tetrahydro-2-methoxy-5 <i>H</i> -carbazole.....	165
First Approach.....	165
Second Approach.....	170
5.3.2 Synthesis of “Upper” Hemisphere Analogue	162
5.4 Experimental Procedures Associated with Work Described in Chapter Four	178
5.4.1 Preparation of (+)-(1 <i>R</i> ,2 <i>S</i> ,5 <i>R</i>)-5-Methyl-2-(2-(naphthalen-3-yl)propan-2-yl)cyclohexyl)cyclohexanol.....	178
5.4.2 General Procedure for Synthesis of Chiral Chloroformates 251 - 253	181
5.4.3 General Procedure for Synthesis of Chiral Cyanoformates 255 - 258	184

5.4.4 General Procedure for Synthesis of Chiral β -Ketoesters 259 - 262	187
5.4.5 General Procedure for Synthesis of Chiral α -Arylated β -Ketoesters 263 - 266	191
5.5 References.....	185
Appendix A: Schemes Summarising Existing Total Syntheses of (+)-Vinblastine.....	197

Corrigendum

- (i) Page iv, Line 11 and Page 21, Line 6: replace “mimicing” with “mimicking”.
- (ii) Page vii, Line 8: replace “to” with “in”.
- (iii) Page xii, Line 12: The definition for TFA should read “trifluoroacetyl or trifluoroacetic acid”.
- (iv) Page 1, Line 2: replace “amendable” with “amenable”.
- (v) Page 3, Lines 2, 3 and 4: Should read, “Towards the end of the event, the microtubules begin to form and conglomerate towards the newly formed chromosomes. This event creates the mitotic spindles”.
- (vi) Page 5, Fig 1.3: Insert reference number 5 at end of caption.
- (vii) Page 8, Line 8, replace “exhibits” with “exhibit”.
- (viii) Page 8, Line 22: remove “in”.
- (ix) Page 12, Line 2, Page 198, Scheme A:1 and references 16, 34 and 35 in Chapter One: replace “Poiter” with “Potier”.
- (x) Page 15, Line 4: replace “piperidine” with “nitrogen-containing”.
- (xi) Page 29, Line 1: replace “Nillson” with “Nilsson”.
- (xii) Page 45, Line 2: replace “tetrahydocarbazoles” with “tetrahydrocarbazoles”.
- (xiii) Page 47, Line 1: replace “as” with “is”.
- (xiv) Page 71, Line 18: replace “isolatable” with “isolable”.
- (xv) Page 80, Table 3.5, Entry 8: replace “LIHMDS” with “LiHMDS”.
- (xvi) Page 105, Line 23: replace “273” with “265”.
- (xvii) Page 121: Compound **87** should be the free alcohol and not the triflate.
- (xviii) Page 202, Scheme A.6: The product shown after step c should be the amide not the illustrated thioamide.
- (xix) References: Replace “*Tetrahedron Ass*” with “*Tetrahedron: Asymmetry*”; “*Aus. J. Chem.*” with “*Aust. J. Chem.*” and “*Org. Prep. Proced. Int.*” with “*Org. Prep. Proceed. Int.*”